AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...

Long-term follow-up shows all patients who demonstrated sustained disability improvement (SDI) maintained it at all subsequent timepoints 50 percent of patients in the two highest dose Cohorts (3 and ...